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Attenuated Salmonella enterica serovar Typhimurium expressing recombinant antigens from other pathogens
elicits primarily a Th1-type dominant immune response to both recombinant and Salmonella antigens. The
immunogenicity and appropriate subcellular location of the recombinant antigen in the Salmonella vaccine
strain may contribute to augmenting immune responses by facilitating adequate exposure of recombinant
antigen to antigen-presenting cells for processing. To allow for secretion from gram-negative bacteria and
overexpression of antigen, a DNA fragment encoding a highly antigenic -helical region of PspA (pneumo-
coccal surface protein A) was subcloned downstream from the -lactamase signal sequence in the multicopy
Asd pYA3493 vector to create pYA3494. pYA3493 was derived from a class of Asd vectors with reduced
expression of Asd to minimize selective disadvantage and enhance immunization of expressed recombinant
antigens. The S. enterica serovar Typhimurium vaccine strain was constructed by the introduction of deletion
mutations crp-28 and asdA16. Approximately 50% of the recombinant PspA (rPspA) expressed in a Salmo-
nella strain harboring pYA3494 was detected in the combined supernatant and periplasmic fractions of
broth-grown recombinant Salmonella. After a single oral immunization in BALB/c mice with 109 CFU of the
recombinant Salmonella vaccine strain carrying pYA3494, immunoglobulin G (IgG) antibody responses were
stimulated to both the heterologous antigen rPspA and Salmonella lipopolysaccharide (LPS) and outer mem-
brane proteins (OMPs). About half, and even more at later times after immunization, of the antibodies induced
to rPspA were IgG1 (indicating a Th2-type response), whereas 60 to 70% of the antibodies to LPS and 80 to 90%
of those to OMPs were IgG2a (indicating a Th1-type response). A sublethal infection with Streptococcus
pneumoniae WU2 boosted PspA antibody levels and maintained IgG2a/IgG1 ratios similar to those seen before
the challenge. Oral immunization with Salmonella-PspA vaccine protected 60% of immunized mice from death
after intraperitoneal challenge with 50 times the 50% lethal dose of virulent S. pneumoniae WU2.
Orally administered Salmonella enterica serovar Typhi-
murium colonizes the gut-associated lymphoid tissue (Peyer’s
patches) and the secondary lymphatic tissues, including the
liver and spleen, to elicit anti-Salmonella immune responses
during infection of the mouse. (17). The immune responsive-
ness to orally administered Salmonella has been applied to
develop live attenuated oral Salmonella vaccines (13). Atten-
uated Salmonella vaccines have been constructed by introduc-
tion of mutations in the genes required for virulence, including
the cyclic AMP receptor protein gene (crp) (12). Crp is a global
regulator involved in a variety of biological functions, including
carbohydrate utilization (4). Attenuated Salmonella vaccine
strains have been genetically modified to express another
pathogen’s antigen (s) specified by multicopy plasmids. These
recombinant vaccines induce immunity to the pathogen whose
antigen gene is expressed as well as to Salmonella. It is essen-
tial that the antigen-specifying plasmids in Salmonella vaccines
are stably maintained during the in vivo colonization process.
A balanced-lethal host-vector system based on the essential
bacterial gene for aspartate -semialdehyde dehydrogenase
(asd) has been used to specify recombinant antigens from
Asd plasmids that are retained in vivo in Salmonella vaccine
strains with the asd gene deleted (16, 36).
Streptococcus pneumoniae is a human pathogen that causes
life-threatening diseases, including community-acquired pneu-
monia, otitis media, meningitis, and bacteremia, in persons of
all ages (35). S. pneumoniae is the leading cause of childhood
pneumonia worldwide, resulting in about 3 million deaths per
year (21). The recent emergence of antibiotic-resistant strains
has the potential to threaten the treatment of pneumococcal
disease in the near future (5). Thus, the development of a safe,
effective, and lower-cost antipneumococcal vaccine is urgently
needed. Capsular polysaccharide-based pneumococcal vac-
cines are currently available and are moderately effective. A
23-valent pneumococcal polysaccharide vaccine is recom-
mended for the prevention of infection in adults (48), and a
7-valent conjugated polysaccharide vaccine is licensed for use
in children (49). However, vaccination with the pneumococcal
polysaccharide vaccine does not reduce the frequency of hos-
pitalization, costs, and mortality caused by pneumococcal
pneumonia (23), which reinforces the need for effective new
vaccines.
Studies on the protective efficacy of subunit vaccines may
further the development of a more protective pneumococcal
vaccine. The pneumococcal PspA (pneumococcal surface pro-
tein A) protein has been evaluated and considered to be a
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pneumococcal vaccine candidate because of its immunogenic-
ity and protection of mice against challenge with virulent S.
pneumoniae (6, 8, 9, 25). Native PspARx1 (PspA originating
from S. pneumoniae strain Rx1) contains several functional
domains: an N-terminal signal sequence, an -helical region, a
proline-rich domain, 10 tandem-repeat choline-binding re-
gions, and a 17-amino-acid residue carboxy terminus. Pneumo-
coccal protection assays with mice immunized with various
recombinant PspARx1 oligopeptides showed that the -helical
domain contains the protective epitopes (7). In a previous
study, mice orally immunized with an S. enterica serovar Ty-
phimurium vaccine strain expressing a recombinant PspARx1
(from the ATG start codon specifying the native signal se-
quence, the entire -helical domain, and up to the fifth tandem
repeat) showed PspA-specific immune responses and were
protected against challenge with virulent S. pneumoniae (37).
Expression of recombinant PspA (rPspA) in this recombinant
Salmonella vaccine strain was somewhat toxic, such that the
high-copy-number plasmid pYA3193 (pUC ori) was relatively
unstable. Thus, approximately 50% of cells lost the plasmid
after 24 h of growth as a standing culture in the presence of
diaminopimelic acid (DAP). This phenomenon forced us to
construct an improved plasmid vector to enable stable expres-
sion of rPspA in attenuated Salmonella. An additional goal of
our research is to construct recombinant attenuated Salmo-
nella vaccines that induce higher immune responses to the
foreign expressed antigen than to Salmonella antigens.
In this work, we constructed a stable multicopy Asd anti-
gen expression vector encoding the -lactamase signal se-
quence fused in frame to the immunogenic -helical region of
PspA. This plasmid was designed to translocate PspA into the
periplasmic space of the Salmonella vaccine strain, although
about 25% of the synthesized PspA reached the supernatant
fluid without cell lysis. We report the immunogenicity, type of
immune responses, and protection against both Salmonella and
S. pneumoniae in mice immunized with a Salmonella vaccine
expressing rPspA by an improved antigen expression system.
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and growth conditions. The bacterial
strains and plasmids used in this study are listed in Table 1. Bacteriophage
P22HTint (46) was used for generalized transduction. Escherichia coli and S.
enterica serovar Typhimurium cultures were grown at 37°C in Lennox broth (29)
or Luria-Bertani (LB) broth or on LB agar (1). MacConkey agar (Difco, Detroit,
Mich.) supplemented with 1% sugar was used for fermentation assays. When
required, antibiotics were added to culture media at the following concentra-
tions: ampicillin, 100 g/ml; chloramphenicol, 30 g/ml; kanamycin, 50 g/ml;
and tetracycline, 15 g/ml. DAP was added (50 g/ml) for the growth of Asd
strains (36). LB agar containing 5% sucrose was used for sacB gene-based
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristicsa Derivation, source, or reference
Strains
E. coli
6212 F  80 	(lacZYA-argF) endA1 recA1 hsdR17 deoR thi-1 glnV44
gyrA96 relA1 	asdA4
36
MGN-617 thi-1 thr-1 leuB6 fhuA21 lacY1 glnV44 	asdA4 recA1 RP4 2-Tc::Mu
[pir]; Kmr
44
S. enterica serovar Typhimurium
3339 SL1344 hisG 22
4550 SR-11 gyrA1816 	crp-1 	asdA1 	(zhf-4::Tn10) 	cya-1 47
4746 3339 nadA540::Tn10 	(galE-chl-uvrB)-1005; Tetr Lab collection
8499 hisG 	crp-28 3339
8501 hisG 	crp-28 	asdA16 8499
8554 hisG 	asdA16 3339
8599 hisG 	asdA16 atrB13::MudJ 8554
JF2430 LT2 atrB13::MudJ 15
S. pneumoniae WU2 Wild-type virulent, encapsulated type 3 6
Plasmids
pYA3193 Asd vector harboring 1.5-kb C-terminally truncated pspA gene;
pUCori
37
pYA3333 Asd; pBRori Lab collection
pYA3334 Asd; pUCori Lab collection
pYA3341 Asd; pUCori This study
pYA3342 Asd; pBRori This study
pYA3493 pYA3342 derivative -lactamase signal sequence-based periplasmic
secretion plasmid
This study
pYA3494 0.7-kb DNA encoding the -helical region of PspA in pYA3493 This study
pYA3496 0.7-kb DNA encoding the -helical region of PspA in pYA3342
for the expression of His-tagged PspA
This study
pBR322 Cloning vector; Apr Tcr 3
pMEG-443 Recombinant suicide plasmid to generate Salmonella 	asdA16
mutant; Apr Cmr
27
pMEG-493 Recombinant suicide plasmid to generate Salmonella 	crp-28
mutant; Apr Cmr
Megan Health Inc.
a Apr, ampicillin resistance; Cmr, chloramphenicol resistance; Kmr, kanamycin resistance; Tcr, tetracycline resistance.
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counterselection in allelic exchange experiments (18). S. pneumoniae WU2 was
cultured on brain heart infusion agar containing 5% sheep blood or in Todd-
Hewitt broth plus 0.5% yeast extract (6).
General DNA procedures. DNA manipulations were carried out as described
by Sambrook et al. (45). Transformation of E. coli and Salmonella was done by
electroporation (Bio-Rad, Hercules, Calif.). Transformants containing Asd
plasmids were selected on L agar plates without DAP. Only clones containing the
recombinant plasmids were able to grow under these conditions. Transfer of
recombinant suicide plasmids to Salmonella was accomplished by conjugation
using E. coli MGN-617 (Asd) (44) as the plasmid donor. Bacteriophage P22HT
int-mediated general transduction was performed by standard methods (52).
PCR amplification was employed to obtain DNA fragments for cloning and for
verification of chromosomal deletion mutations. The PCR conditions were as
follows: denaturation at 95°C for 20 s, primer annealing at 55°C for 20 s, poly-
merization at 72°C for 2 min, and a final extension at 72°C for 10 min. Nucleotide
sequencing reactions were performed using ABI Prism fluorescent Big Dye
terminators according to the instructions of the manufacturer (PE Biosystems,
Norwalk, Conn.).
Characterization of phenotype. MacConkey agar supplemented with 1% mal-
tose was used to detect the phenotypes of Salmonella crp mutants. Motility was
evaluated by observing Salmonella spread on a semisolid medium composed of
1% casein enzyme hydrolysate, 0.5% NaCl, and 0.5% agar. Triphenyltetrazolium
chloride (50 g/ml) was added to motility medium to observe Salmonella as red
cells. The presence of the 	asdA16 mutation in Salmonella was confirmed by
inability of the strain to grow on media without DAP (36). Lipopolysaccharide
(LPS) profiles of Salmonella strains were examined by previously described
methods (24).
SDS-PAGE and immunoblot analyses. Protein samples were boiled for 5 min
and then separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Protein bands were visualized by Coomassie bril-
liant blue R250 (Sigma, St. Louis, Mo.) staining. For immunoblotting, proteins
separated by SDS-PAGE were transferred eletrophoretically to nitrocellulose
membranes. The membranes were blocked with 3% bovine serum albumin in 10
mM Tris–0.9% NaCl (pH 7.4) and incubated with mouse monoclonal antibodies
specific for PspA (Xi126) (32), OmpC (50), or -galactosidase (Sigma) and then
with a peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (Bio-
Rad). Immunoreactive bands were detected by the addition of 4-chloro-1-naph-
thol (Sigma) in the presence of H2O2. The reaction was stopped after 2 min by
washing with several large volumes of deionized water.
Purification of rPspA. For overexpression of His6-tagged PspA, a fragment of
the pspA gene specifying the -helical region from amino acid residue 3 to 257
of the mature PspA protein of S. pneumoniae Rx1 was PCR amplified from






). The 0.8-kb amplified
fragment was then cloned into the pYA3342 vector, resulting in pYA3496 (Table
1). The N-terminal primer contains an EcoRI site (underlined) and six consec-
utive histidine codons (alternate use of CAT and CAC; boldface) for His6
tagging at the N terminus. The C-terminal primer specifies two consecutive stop
codons (TAA TAG; boldface) followed by a HindIII site (underlined). In-frame
cloning was confirmed by nucleotide sequencing. E. coli 6212 harboring
pYA3496 expressed a large amount of soluble His6-tagged rPspA in its cyto-
plasm. According to the protocol of the manufacturer (Qiagen, Valencia, Calif.),
rPspA protein was purified by an affinity purification process with Ni2-nitrilo-
triacetic acid-agarose support. The protein purity was verified by Coomassie blue
staining of SDS-polyacrylamide gels, and the total amount of purified protein
was determined by using the Pierce (Rockford, Ill.) protein assay kit with bovine
serum albumin as a standard. Immunoblotting with the Xi126 PspA monoclonal
antibody (32) was performed to confirm the purified protein.
Salmonella subcellular fractionation. The periplasmic fraction was prepared
by a modification of the lysozyme-osmotic shock method (56). Cultures grown in
LB broth to an optical density at 600 nm (OD600) of 0.8 were centrifuged at 7,000
 g for 10 min, and the supernatant fluid was saved for analysis of secreted
proteins. The cell pellets were resuspended in 800 l of 100 mM Tris-HCl buffer
(pH 8.6) containing 500 mM sucrose and 0.5 mM EDTA. Hen egg white ly-
sozyme (40 l of a 4-mg/ml stock solution) was added, followed immediately by
the addition of 3.2 ml of 50 mM Tris-HCl buffer (pH 8.6) containing 250 mM
sucrose, 0.25 mM EDTA, and 2.5 mM MgCl2. After gentle agitation, the sus-
pension was incubated for 15 min in an ice bath. Cells were removed by centrif-
ugation at 7,000  g for 6 min followed by filtration of the supernatant through
a 0.45 m-pore-size filter. The filtered supernatant fluid served as the periplas-
mic fraction. Cells resuspended in 4 ml of 20 mM Tris-HCl (pH 8.6) were
disrupted by two passages through a French pressure cell (American Instrument
Company, Silver Spring, Md.). Cell lysates were centrifuged at 7,000  g at 4°C
for 6 min to remove unbroken cells. The supernatant fluid was then centrifuged
at 132,000  g at 4°C for 1 h to separate the soluble fraction and insoluble cell
envelopes. The soluble fraction contained the cytoplasmic proteins. To isolate
the outer membrane fraction, total envelope pellets were suspended in 4 ml of 20
mM Tris-HCl (pH 8.6) containing 1% Sarkosyl and incubated for 30 min on ice.
The outer membrane fraction was obtained as a pellet after centrifugation at
132,000 g at 4°C for 1 h. The pellet was resuspended in 4 ml of 20 mM Tris-HCl
buffer (pH 8.6). The original culture supernatant was filtered (0.22 m-pore-size
filter), and secreted proteins were precipitated with 10% trichloroacetic acid (1
h, 4°C). An equal volume of each fraction sample was separated by SDS-PAGE
for Western blot analysis. By using the outer membrane protein preparation
procedure described above, Salmonella outer membrane proteins (SOMPs) were
prepared from S. enterica serovar Typhimurium 4746 cells grown in LB broth
without galactose for analysis by enzyme-linked immunosorbent assay (ELISA).
The use of SOMPs obtained from 4746 precludes LPS O-antigen contamina-
tion.
Construction of an S. enterica serovar Typhimurium vaccine strain. The 	crp
mutation was introduced into S. enterica serovar Typhimurium 3339 by allelic
exchange using the suicide vector pMEG-493 to yield 8499. The presence of the






a strain phenotype of Mal and nonmotility. The 	asdA16 mutation was then
introduced into 8499 by P22HTint transduction from 8554 with the suicide
vector pMEG-443 integrated into a strain with the 	asdA16 mutation, followed
by sucrose selection to eliminate the suicide vector to yield 8501 (27). The
presence of the 1,242-bp asd deletion in 8501 was confirmed by PCR using






Immunization of mice. Two groups of five inbred 7-week-old female BALB/c
mice were deprived of food and water for 4 h before infection. The recombinant
S. enterica serovar Typhimurium 8501(pYA3494) vaccine (1.9  109 CFU in 20
l of phosphate-buffered saline containing 0.01% gelatin [BSG]) grown in LB
broth to an OD600 of 0.8 was orally administered to BALB/c mice. The recom-
binant S. enterica serovar Typhimurium 8501(pYA3493) vaccine (2  109 CFU
in 20 l of BSG) was used as a vector control. Food and water were returned to
the immunized mice 30 min after immunization. Blood was obtained by retro-
orbital puncture with heparinized capillary tubes at biweekly intervals. Following
centrifugation at 4,000  g for 5 min, the serum was removed from the whole
blood and stored at 20°C. Vaginal secretion specimens were collected in a
50-l BSG wash and stored at 20°C (59).
Pneumococcal challenge. To observe the immune response caused by pneu-
mococcal infection after vaccination, a sublethal dose of 3.8 105 S. pneumoniae
WU2 CFU in 200 l of BSG was administered by intravenous (i.v.) injection to
S. enterica serovar Typhimurium vaccine-immunized BALB/c mice at 16 weeks
after primary immunization. The ability of the Salmonella-PspA vaccine to pro-
tect the immunized mice against S. pneumoniae was assessed by intraperitoneal
challenge with 4.8 103 CFU of S. pneumoniae in 100 l of BSG. The 50% lethal
dose (LD50) of S. pneumoniae WU2 in BALB/c mice was 106 CFU by i.v.
administration (Larry McDaniel, personal communication) and 102 CFU by
intraperitoneal administration (37). Significant differences in mortality were de-
termined by chi-square analysis at day 21 after challenge. A difference was
considered significant at a P value of 0.05.
ELISA. ELISA was used to assay antibodies in vaginal secretions and serum to
S. enterica serovar Typhimurium LPS and SOMPs and to rPspA. Polystyrene
96-well flat-bottom microtiter plates (Dynatech Laboratories Inc., Chantilly, Va.)
were coated with S. enterica serovar Typhimurium LPS (100 ng/well; Sigma),
SOMPs (100 ng/well), or purified rPspA (100 ng/well). Antigens suspended in
sodium carbonate-bicarbonate coating buffer (pH 9.6) were applied with 100-l
volumes in each well. The coated plates were incubated at 37°C for 1 h, followed
by an overnight incubation at 4°C. Free binding sites were blocked with a
blocking buffer (phosphate-buffered saline [pH 7.4], 0.1% Tween 20, and 1%
bovine serum albumin). Vaginal secretions and sera obtained from the same
experimental group (five mice per group) were pooled and diluted 1:10 and
1:600, respectively. A 100-l volume of diluted sample was added to individual
wells in duplicate and incubated for 2 h at 37°C. Plates were treated with
biotinylated goat anti-mouse IgG, IgG1, or IgG2a (Southern Biotechnology Inc.,
Birmingham, Ala.) for sera and IgA for vaginal secretions. Wells were developed
with streptavidin-alkaline phosphatase conjugate (Southern Biotechnology) fol-
lowed by p-nitrophenylphosphate substrate (Sigma) in diethanolamine buffer
(pH 9.8). Color development (absorbance) was recorded at 405 nm using an
automated ELISA plate (model EL311SX; Biotek, Winooski, Vt.). Absorbance
VOL. 70, 2002 ANTIBODY RESPONSES ELICITED BY SALMONELLA-rPspA VACCINE 1741
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readings two times higher than preimmune serum baseline values were consid-
ered positive reactions.
RESULTS
Construction of Asd vectors to use for antigen expression.
Vaccine strains harboring mulicopy Asd vectors (pBR ori or
pUC ori) containing the entire asd gene with its promoter
synthesized the Asd protein at a much higher level than nec-
essary to complement the chromosomal asd mutation in a
balanced-lethal host-vector system. In fact, the 200- to 300-fold
excess production of Asd in a strain such as 8554 (	asd16)
with the pYA3334 Asd vector (pUC ori) increases the gen-
eration time slightly and the LD50 10-fold compared to the
same strain with an Asd vector with the pSC101 ori or p15A
ori. In an attempt to reduce the level of Asd, the asd promoter
region was deleted to determine whether there would be suf-
ficient transcription to permit a promoterless asd gene to com-
plement the chromosomal 	asdA16 mutation. The asd gene
sequence was amplified by PCR starting at bp 286 and ending
at bp 1421 of the S. enterica serovar Typhimurium asd se-
quence (accession number AF015781) with an N-terminal
BglII site and a C-terminal XbaI site. This sequence contains
the Shine-Dalgarno (SD) sequence for ribosome recognition
but lacks the 35 and 10 promoter sequence and ends just
after the asd gene TAG stop codon. The BglII-XbaI DNA
fragment was used to construct Asd vectors pYA3342 (pBR
ori) and pYA3341 (pUC ori) (Table 1). It was possible to clone
this fragment onto pSC101 ori or p15A ori vectors, but this did
not result in sufficient Asd to permit construction of balanced-
lethal systems with strains such as 8554 which could grow in
the absence of DAP. Both pYA3342 and pYA3341 comple-
mented the asd mutations of E. coli 6212 and S. enterica
serovar Typhimurium 4550. Salmonella strains possessing
pYA3342 and pYA3341 produced significantly reduced
amounts of Asd protein (39 kDa) compared to strains contain-
ing plasmids that had asd genes with the asd native promoter
(Fig. 1). pYA3342 and pYA3341 in a 	asd S. enterica serovar
Typhimurium strain such as 8554 yielded recombinants that
had wild-type LD50s following oral inoculation of BALB/c
mice. Plasmid pYA3342 (Fig. 2A) was used for further con-
struction.
Since export of PspA into the periplasmic space of Salmo-
nella was inefficient and caused toxicity when the export de-
pended on the signal sequence for PspA (37), we constructed
a recombinant plasmid by cloning a DNA fragment specifying
the signal sequence of -lactamase which is efficiently trans-
ported into the periplasmic space in Salmonella. A 105-bp
DNA fragment (nucleotides 4049 to 4153 of the sequence
under accession number J01749) of the -lactamase gene was
PCR amplified from the pBR322 DNA template by using a
pair of primers (N-terminal, 5
GCATTCATGAGTATTCAA
CATTTCC3
-BspHI [underlined]; C-terminal, 5
CCGGAATT
CTTCAGCATCTTTTACT3
-EcoRI [underlined]). The PCR-
amplified fragment included the N terminus of -lactamase
from the ATG start codon through the signal sequence (23
amino acids) plus 12 amino acids of the N terminus of the
mature -lactamase. These additional 12 amino acid residues
were included to increase the efficiency of secretion of the
recombinant protein (53). The 105-bp PCR product was di-
gested with BspHI and EcoRI enzymes and cloned into the
NcoI site (compatible with the BspHI site) and EcoRI site of
the Asd vector pYA3342, resulting in plasmid pYA3493 (Fig.
2B). The in-frame position of the -lactamase signal sequence
was confirmed by nucleotide sequencing. Transcription pro-
moted by Ptrc can be stopped by the 5ST1T2 transcriptional
terminator located following the multicloning sites. pYA3493
was stably maintained for 50 or more generations in E. coli
6212 and S. enterica serovar Typhimurium (	asd) hosts grown
in the presence or absence of DAP.
Construction of the rPspA-expressing plasmid. A highly im-
munogenic -helical region of PspA from amino acid residue 3
to 257 (765 bp; 255 amino acids) of the mature PspARx1 pro-
tein (588 amino acids) was selected to use as a test antigen in
antigen delivery by a Salmonella carrier. The 765-bp DNA
fragment of the pspA gene of S. pneumoniae Rx1 was PCR




; C-terminal, same as used in the construction
of His6-tagged PspA, which introduces the TAA TAG stop
codons after the pspA coding sequences). The PCR product,
digested with EcoRI and HindIII enzymes, was cloned into the
EcoRI and HindIII sites of pYA3493, resulting in pYA3494
(Fig. 3). The in-frame fusion of the rPspA with the -lactamase
signal sequence was confirmed by nucleotide sequencing. E.
coli 6212 harboring pYA3494 expressed rPspA as approxi-
mately 1% of the total cell protein (data not shown).
Expression and subcellular localization of rPspA in Salmo-
nella. An S. enterica serovar Typhimurium strain was con-
structed to examine expression and subcellular localization of
rPspA. The atrB13::MudJ allele (15), causing constitutive ex-
pression of -galactosidase, in S. enterica serovar Typhimurium
FIG. 1. Reduced expression of Asd protein by deletion of the asd
gene promoter region. SDS-PAGE was performed with cell lysates of
S. enterica serovar Typhimurium 4550 with pYA3333 (entire asd gene
with Pasd, pBR ori), pYA3334 (entire asd gene with Pasd, pUC ori),
pYA3342 (promoterless SD-asd gene, pBR ori), and pYA3341 (pro-
moterless SD-asd gene, pUC ori). Standards are indicated to the left,
and Asd protein (39 kDa) is indicated by an arrow. Lanes; 1, pYA3333;
2, pYA3334; 3, pYA3342; 4, pYA3341.
1742 KANG ET AL. INFECT. IMMUN.
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JF2430 was transduced into S. enterica serovar Typhimurium
8554 by P22HTint-mediated generalized transduction (52),
resulting in 8599 (hisG 	asdA16 atrB13::MudJ). 8599 was
Lac on MacConkey agar plus lactose and DAP. -Galacto-
sidase production from the atrB13::MudJ allele in 8599 was
used as a cytoplasmic protein marker and as an indicator of
membrane leaking in the examination of subcellular fraction-
ations. No periplasmic protein marker was used, since the use
of the -lactamase signal sequence in the pYA3494 construct
precluded use of -lactamase and the commercially available
monoclonal antibody to the E. coli maltose binding protein
(Sigma) did not react with this protein from S. enterica serovar
Typhimurium. To observe rPspA expression, plasmid
pYA3494 was introduced into S. enterica serovar Typhimurium
8599. 8599 harboring pYA3493 (vector alone) was used as
the control (data not shown).
With the expectation of the periplasmic secretion of the
rPspA, various subcellular fractions, including cytoplasm,
periplasm, outer membrane, and culture supernatant of
8599(pYA3494), were prepared to examine the location of
rPspA. Although the calculated size of rPspA was approxi-
mately 30 kDa, PspA-specific monoclonal antibody Xi126 re-
acted with an approximately 35-kDa protein (Fig. 4). Aberrant
migration of a PspA protein has been seen in previous studies
(37, 54). Although a large amount of the rPspA resided in the
cytoplasmic fraction, half of the rPspA was detected in the
periplasmic fraction and the culture supernatant fluid. Little or
no rPspA was detected in the outer membrane fraction. Den-
sitometry analyses of immunoreactive bands showed that ap-
proximately 50% of the rPspA was located in the combined
periplasm (25%) and culture supernatants (25%). In the im-
munoblot analyses of subcellular fractions with anti--galacto-
sidase and -OmpC monoclonal antibodies, the -galactosidase
and OmpC proteins were detected in the cytoplasm and outer
membrane fractions, respectively, suggesting that the rPspA
detected in the periplasmic fraction and culture supernatant
fluid was actively secreted instead of resulting from nonspecific
membrane leaking or cell death by lysis.
Recombinant S. enterica serovar Typhimurium crp-28 vac-
cine expressing rPspA antigen. pYA3493 (vector control) and
pYA3494 (encoding rPspA) were electroporated into the
	crp-28 	asdA16 strain 8501. The S. enterica serovar Typhi-
murium 8501 (	crp-28 	asdA16) vaccine strain containing
pYA3494 expressed the rPspA protein at an approximate mo-
lecular mass of 35 kDa. In the analyses of Coomassie blue-
stained SDS-polyacrylamide gels, the amount of rPspA protein
was as much as approximately 1 to 2% of the total
8501(pYA3494) proteins (Fig. 5). With results consistent with
those seen in the rPspA localization analysis (75% of rPspA
cell associated [50% in cytoplasm and 25% in periplasm] and
25% of rPspA secreted), the rPspA expressed in the 8501
vaccine strain was secreted into the culture supernatant along
with other secreted proteins. To examine the stability of plas-
mids pYA3493 and pYA3494 in Salmonella 8501 in vitro,
FIG. 2. Asd antigen expression vectors. (A) Asd vector pYA3342. The map of pYA3342 and the nucleotide sequences of the Ptrc promoter
region and multicloning sites are shown. (B) Periplasmic secretion Asd vector pYA3493. A DNA fragment encoding the -lactamase signal
sequence and 12 amino acid residues of the N terminus of mature -lactamase of plasmid pBR322 was positioned under the control of the Ptrc
promoter of the Asd vector pYA3342 (pBR ori). The map of pYA3493 and the nucleotide sequences of the Ptrc promoter region, -lactamase
signal sequence (bla SS), and multicloning sites are shown. The Ptrc sequences for 35, 10, and SD are indicated, and the translation start codon
is in boldface. An arrow within the sequence indicates the signal peptidase cleavage site. Unique restriction enzyme sites in the multicloning site
are indicated. 5ST1T2 is a transcriptional terminator.
VOL. 70, 2002 ANTIBODY RESPONSES ELICITED BY SALMONELLA-rPspA VACCINE 1743
 o
n
 January 13, 2014 by W







8501 cells containing pYA3493 and pYA3494 were cultured
with daily passage of 1:1,000 dilutions for five consecutive days
in L broth containing DAP. All 8501 clones examined (300
clones/day) kept the Asd plasmid pYA3493 and pYA3494,
indicating that pYA3493 and pYA3494 were very stable in the
8501 vaccine strain. Cells obtained from the last-day culture
of the stability test expressed amounts of the 35-kDa rPspA
similar to those from the first day (data not shown), suggesting
stable expression of rPspA without rearrangements.
Immune responses in mice after oral immunization with the
recombinant S. enterica serovar Typhimurium vaccines. All
mice orally administered a single dose of 1.3  109 CFU S.
enterica serovar Typhimurium 8501(pYA3493) (vector con-
trol) survived for the 30-day monitoring period. Those mice
were protected for a 30-day observation period against wild-
type 3339 (LD50, 10
6 CFU) challenge (1.7  109 CFU) 30
days after the initial immunization. There were no survivors in
a group of unimmunized mice challenged with 1.7  107 CFU
of 3339. These results indicate that 8501 with an Asd
vector is avirulent for mice and elicits a protective immune
response against challenge with S. enterica serovar Typhi-
murium.
A single dose of S. enterica serovar Typhimurium
8501(pYA3494) (1.9  109 CFU) or 8501(pYA3493) (con-
trol, 2  109 CFU) was orally administered to 7-week-old
female BALB/c mice. All immunized mice survived, and we did
not observe any signs of disease in the immunized mice during
the entire experimental period. The antibody responses to
Salmonella LPS and SOMPs and to the foreign antigen rPspA
in the sera and the vaginal secretions of the immunized mice
were measured. The serum IgG responses to LPS, SOMPs, and
rPspA are presented in Fig. 6. At 2 weeks after administration,
little IgG response to the antigens was observed. Maximal
anti-LPS, -SOMP, and -rPspA IgG levels without boost immu-
nization were detected at 6 weeks postimmunization.
At 17 weeks postimmunization, we infected mice i.v. with a
sublethal dose (3.8  105 CFU) of the virulent S. pneumoniae
WU2 strain to monitor the changes of anti-rPspA antibody
titers. Sublethal i.v. infection with S. pneumoniae did not kill
mice immunized with the 8501(pYA3493) or 8501
(pYA3494) vaccine. Because native PspA is a highly immuno-
genic pneumococcal surface protein, the pneumococcal chal-
lenge boosted rPspA-specific immune responses in 8501
(pYA3494)-immunized mice (Fig. 6). In comparison to the
anti-rPspA IgG level (A405, 0.81) at 12 weeks after S. enterica
FIG. 3. Recombinant plasmid pYA3494 for PspA expression.
(A) The PspA region used in this study. Functional domains of native
PspA from S. pneumoniae (PspARx1) are diagramed. Dotted box,
leader sequence (31 amino acids [aa]); open box, immunodominant
-helical region (aa 1 to 288); hatched box, proline-rich region (aa 289
to 370); 10 gray boxes, choline-binding repeats (aa 371 to 571); black
box, C terminus (aa 572 to 588). Dotted lines represent the limit of the
rPspA region used in this study. Bioinformatical analyses of the rPspA
for antigenic index and surface probability are presented. Analyses
were performed with the Protean module of the Lasergene sequence
analysis software. (B) Map of recombinant plasmid pYA3494. A 0.7-kb
EcoRI-HindIII fragment of PCR-amplified DNA of pspARx1 was
cloned into the EcoRI and HindIII sites of pYA3493 (Fig. 2B). The
cloned fragment included the immunogenic -helical region of PspA
including amino acids 3 through 257 of mature PspA (255 amino
acids).
FIG. 4. Subcellular location of expressed rPspA in S. enterica sero-
var Typhimurium. Subcellular fractions were prepared from S. enterica
serovar Typhimurium 8599(pYA3494) cells grown in LB broth at
37°C by the procedures described in Materials and Methods. Fractions
equivalent to 30-l volumes of the culture at an OD600 of 0.8, except
for supernatant fluids, were analyzed by SDS-PAGE, and the rPspA
was detected by immunoblotting with PspA-specific monoclonal anti-
body Xi126 (33). -Galactosidase and OmpC were used as fraction-
ation controls for cytoplasmic and outer membrane fractions, respec-
tively. Standards are indicated to the left. Lanes: 1, total cell lysate; 2,
cytoplasm; 3, periplasm; 4, outer membrane; 5, concentrated superna-
tant (750 l); 6, supernatant (10 l).
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serovar Typhimurium 8501(pYA3494) immunization, the
pneumococcal challenge boosted 53% more anti-rPspA IgG
(A405, 1.24) 1 week later. This suggests that the S. enterica
serovar Typhimurium 8501-rPspA vaccine induces immuno-
logical memory for a rapid responsiveness to subsequently
administered PspA antigen. Anti-rPspA IgG was not detected
in sera obtained from mice immunized with 8501(pYA3493),
the vector control vaccine. The 8501(pYA3493) vaccine elic-
ited anti-LPS and -SOMP IgG responses with kinetics and
levels similar to those induced by 8501(pYA3494). These
results suggest that Salmonella-delivered rPspA antigen had
minimal influence on the immune response to Salmonella it-
self.
IgA levels, mostly secretory IgA, for LPS, SOMPs, and
rPspA in the vaginal fluids of immunized mice were measured.
The 8501(pYA3493) and 8501(pYA3494) vaccines elicited
anti-LPS and anti-SOMP IgA. rPspA-specific IgA was detected
in the vaginal fluids from mice immunized with 8501
(pYA3494) but not in those from mice immunized with the
8501(pYA3493) vector-only control (Fig. 7).
IgG isotype analyses. The types of immune responses to
Salmonella LPS and SOMPs and to the rPspA were further
examined by measuring the levels of IgG isotype subclasses
IgG2a and IgG1. The Th1-helper cells direct cell-mediated
immunity and promote class switching to IgG2a, and Th2 cells
provide potent help for B-cell antibody production and pro-
mote class switching to IgG1 (39, 51). IgG2a isotype dominant
responses were observed for the Salmonella LPS and SOMP
antigens (Fig. 8). The IgG2a/IgG1 ratios for anti-LPS and
-SOMPs in sera obtained from mice immunized with
8501(pYA3493) were not significantly different from those
from mice immunized with 8501(pYA3494) (LPS, P  0.07;
SOMPs, P  0.054). The IgG2a/IgG1 ratios for anti-SOMPs
(ranging from 6.4 to 11.5) are higher than those for LPS (ranging
from 1.1 to 2.5), with statistical significance [8501(pYA3493),
P 0.0004; 8501(pYA3494), P 0.0003]. Th1-type dominant
immune responses are frequently observed after immunization
with attenuated Salmonella (30, 40). In contrast to the type of
immune responses to LPS and SOMPs, a Th1- and Th2-type
mixed response was observed for the rPspA antigen. Although
the IgG2a levels were higher than IgG1 levels in the early
FIG. 5. Expression of rPspA in the S. enterica serovar Typhi-
murium vaccine strain. 8501 harboring pYA3494 (specifying rPspA)
or pYA3493 (vector control) was cultured in LB broth at 37°C. Total
cells (equivalent to 7.5  108 cells) and concentrated culture superna-
tants (Sup.) (equivalent to 750 l of supernatant of cultures at an
OD600 of 0.8) were subjected to SDS-PAGE analysis. Left panel,
Coomassie brilliant blue-stained gel. Right panel, immunoblot of the
duplicated gel with PspA-specific monoclonal antibody Xi126. Molec-
ular markers are indicated to the left. PspA proteins are indicated by
arrows. Lanes 1 and 2, protein profiles of 8501(pYA3493) and
8501(pYA3494), respectively.
FIG. 6. Serum IgG responses to S. enterica serovar Typhimurium LPS and SOMPs and to rPspA. The data represent IgG antibody levels
induced in mice orally immunized with 8501(pYA3493) (vector control) and 8501(pYA3494) (expressing rPspA) at the indicated weeks after
immunization. ELISA and data analysis are described in Materials and Methods. Arrows indicate sublethal i.v. infection with S. pneumoniae WU2.
VOL. 70, 2002 ANTIBODY RESPONSES ELICITED BY SALMONELLA-rPspA VACCINE 1745
 o
n
 January 13, 2014 by W







phase (up to 8 weeks postimmunization), the level of anti-
rPspA IgG1 isotype antibodies gradually increased. After 10
weeks postimmunization, a 1:1 ratio of IgG2a to IgG1 or IgG1
dominant responses was detected (Fig. 8). The pneumococcal
i.v. challenge stimulated more IgG1 responses (mean IgG2a/
IgG1 ratio, 0.83) to PspA than seen before challenge (mean
IgG2a/IgG1 ratio, 1.49), with statistical significance (P 
0.023).
FIG. 7. Secretory IgA responses to S. enterica serovar Typhimurium LPS and SOMPs and to rPspA. The data represent anti-LPS, -SOMP, and
-rPspA IgA antibody levels in vaginal secretions of BALB/c mice orally immunized with 8501(pYA3493) (vector control) and 8501(pYA3494)
(expressing rPspA) at weeks 4, 6, 8, and 10 after immunization.
FIG. 8. Serum IgG2a and IgG1 responses to S. enterica serovar Typhimurium LPS and SOMPs and to rPspA. The data represent IgG2a and
IgG1 subclass antibody levels to Salmonella LPS and SOMPs and to rPspA in sera of BALB/c mice orally immunized with 8501(pYA3493) (vector
control) and 8501(pYA3494) (expressing rPspA) at the indicated weeks after immunization. Arrows indicate sublethal i.v. infection with S.
pneumoniae WU2. Anti-rPspA IgG2a and IgG1 responses of 8501(pYA3493) (negative control) are not shown. The overall IgG2a/IgG1 ratios
(means  standard deviations) for each antigen are shown above the bars. Statistical analyses were performed with a paired Student t test to
compare the IgG2a/IgG1 ratios for antigens. P values of 0.05 were considered significant. The results were as follows: (i) LPS for 8501(pY3493)
versus 8501(pYA3494), P 0.05; (ii) SOMPs for 8501(pY3493) versus 8501(pYA3494), P 0.05; (iii) LPS for 8501(pYA3493) versus SOMPs
for 8501(pYA3493), P 0.05; (iv) LPS for 8501(pYA3494) versus SOMPs for 8501(pYA3494), P 0.05; (v) PspA before versus after sublethal
challenge of S. pneumoniae, P  0.05; (vi) LPS for 8501(pYA3494) versus PspA for 8501(pYA3494), P  0.05 (before challenge) and P  0.05
(after challenge); (vii) SOMPs for 8501(pYA3494) versus PspA for 8501(pYA3494), P  0.05 (before and after challenge).
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Evaluation of protective immunity. To examine the ability of
Salmonella-rPspA vaccines to protect against pneumococcal
infection, BALB/c mice were immunized with either S. enterica
serovar Typhimurium 8501(pYA3493) (dose of 1.3  109
CFU) or 8501(pYA3494) (dose of 1.7  109 CFU). At 10
weeks after the initial immunization, a second dose of 109 CFU
of each vaccine was administered. We did not detect weakness
or disease signs in vaccinated mice during the immunization
periods. At 5 weeks after the second immunization, mice were
challenged intraperitoneally with 4.8  103 CFU (50 times the
LD50) of S. pneumoniae WU2. Sixty percent of the mice im-
munized with 8501(pYA3494) were protected from pneumo-
coccal challenge, with statistical significance (P  0.05). This
challenge dose killed 100% of unimmunized and 8501
(pYA3493)-immunized mice (Table 2). Following challenge,
mice unimmunized or immunized with 8501(pYA3493) died
much faster, with death at a mean of day 2, than mice immu-
nized with 8501(pYA3494), which died at a mean of day 5.
DISCUSSION
Attenuated Salmonella strains constructed by recombinant
DNA technology have been developed as live vaccines for
humans and animals to prevent disease caused by Salmonella
infections. The ability of live recombinant Salmonella vaccines
to colonize the gut-associated lymphoid tissue (Peyer’s
patches) and visceral lymphoid tissues following oral adminis-
tration is beneficial in that it stimulates all arms of the immune
response, including mucosal, humoral, and cellular immunities
(13, 17, 34). Recombinant Salmonella vaccines have also been
developed as multivalent vaccines to deliver recombinant an-
tigens originating from viruses, bacteria and parasites (13, 34).
Analysis of convalescent-phase sera from patients or animals
infected with bacterial pathogens reveals that the proteins lo-
cated in the envelopes of or secreted by the bacterial patho-
gens act as dominant immunogens for the immune responses
(31, 38, 58). These observations indicate that envelope and
secreted proteins are highly immunogenic and/or more readily
interact with antigen-presenting cells due to their subcellular
location. Translocation of such highly immunogenic antigens
into the cell envelope or secretion from the cell should increase
the strength of the immune response elicited by vaccine strains
expressing foreign antigens. In the development of attenuated
Salmonella-based multivalent vaccines, a preferable system
would have a recombinant antigen secreted from the cytoplasm
of Salmonella vaccines (19, 20). -Lactamase, encoded by the
ampicillin resistance gene, is a well-characterized periplasmic
secreted protein in gram-negative bacteria (43). The -lacta-
mase gene contained in plasmid pBR322 was originally ob-
tained from an S. enterica serovar Paratyphi B isolate (3, 14). It
is well known that -lactamase produced from pBR322 is se-
creted to the periplasmic space of gram-negative bacteria, and
its translocation depends upon the presence of a signal se-
quence consisting of 23 amino acid residues at the N terminus
(26, 43). Evidence obtained from previous studies confirms
that the signal sequence plus an additional 12 amino acids of
the mature -lactamase are required to translocate -lacta-
mase through the cytoplasmic membrane of gram-negative
bacteria (28, 53). Fusion of a protein to the -lactamase signal
peptide promotes the secretion of the fusion protein into the
periplasm of E. coli (42, 53). We reasoned that a protein
antigen attached to the -lactamase signal peptide should be
secreted into the periplasm of Salmonella vaccine strains. The
pYA3493 plasmid (Fig. 2B) constructed in this study was de-
signed to use for the periplasmic secretion of recombinant
antigens for antigen delivery by Salmonella vaccines.
The recombinant plasmid pYA3494 (pBR ori) (Fig. 3) was
constructed for the periplasmic secretion of the -helical re-
gion of the PspARx1. In contrast to the previously described
PspA-specifying pYA3193 (37), pYA3494 was maintained sta-
bly (100%) over 50 generations in the S. enterica serovar Ty-
phimurium vaccine strain grown in the presence of DAP. Both
E. coli and Salmonella containing pYA3494 expressed the
rPspA protein with an apparent molecular mass of 35 kDa, and
the rPspA proteins were detected in the periplasm (25%) as
well as in the culture supernatant (25%) (Fig. 4). The N-
terminal His6-tagged rPspA protein (no apparent signal pep-
tide) expressed in S. enterica serovar Typhimurium 8599 con-
taining pYA3496 was detected only in the cytoplasm and not in
the periplasm of the Salmonella host (data not shown). These
results suggest that the signal peptide and 12 residues of the N
terminus of -lactamase (present in pYA3494) promote the
periplasmic secretion of rPspA. The mechanism to explain how
rPspA was translocated from the periplasm outside cells (Fig.
4 and 5) remains unknown. The secondary and tertiary struc-
tures of rPspA may permit it to traverse through the Salmo-
nella outer membrane. Alternatively, accumulated rPspA in
the periplasm may be encapsulated in membrane vesicles
which are discharged from the cells. Membrane vesicles have
been identified in many gram-negative bacteria (2), and Ciofu
et al. (10) reported that -lactamase was packaged into mem-
brane vesicles and secreted from Pseudomonas aeruginosa. Ap-
proximately 50% of the rPspA remained in the cytoplasm,
perhaps because the amount of endogenous signal peptidase
necessary to process all of the overexpressed rPspA is limiting.
Alternatively, it has been reported that the C-terminal se-
quence of mature -lactamase is important for the efficient
periplasmic secretion of -lactamase, along with the signal
sequence (28).
The immunogenicity and appropriate subcellular location of
rPspA in the Salmonella vaccine strain may contribute to the
TABLE 2. Oral immunization with rPspA-expressing S. enterica
serovar Typhimurium 8501(pYA3494) vaccine protects BALB/c
mice against challenge with virulent S. pneumoniae strain WU2
Vaccinea rPspAexpressionb
Protectionc




8501(pYA3493)  0 1, 2, 2, 3, 3
None (unimmunized) NA 0 1, 2, 2, 2, 3
a Mice were orally immunized a total of two times at 10-week intervals with
109 CFU of indicated vaccine strain per dose.
b , rPspA expressed; , rPspA not expressed; NA, not applicable.
c Five weeks after the last immunization, mice (five mice per group) were
challenged intraperitoneally with approximately 4.8  103 CFU of virulent S.
pneumoniae WU2. The LD50 of WU2 by intraperitoneal infection in unimmu-
nized BALB/c mice was 102 (data not shown). Mortality was monitored for 3
weeks after pneumococcal challenge. Significance was determined by chi-square
analysis. , P  0.05.
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augmented immune responses by facilitating adequate expo-
sure of rPspA antigen to antigen-presenting cells for process-
ing. BALB/c mice orally immunized with a single dose of S.
enterica serovar Typhimurium 8501 expressing rPspA showed
immune responses to both Salmonella antigens and rPspA.
Although there was variation in antibody levels between sam-
ples due to mucus materials in vaginal washings, mucosal anti-
rPspA IgA was detected in vaginal washings only of mice
immunized with Salmonella-rPspA vaccine (Fig. 7). It is likely
that mucosal immunity will act as a primary immune defense
system against natural infection by S. pneumoniae. Detection
of anti-rPspA IgG with a typical antibody response in sera from
Salmonella-rPspA vaccine-immunized mice (Fig. 6) indicates
that the 8501(pYA3494) vaccine likely reached appropriate
lymphoid tissues to stimulate a systemic immune response.
Similar levels of anti-LPS and -SOMP IgG were induced by
strains 8501(pYA3493) (vector) and 8501(pYA3494), sug-
gesting that rPspA-specific immunity did not interfere with
immunity against Salmonella itself.
In T-cell-dependent, antigen-specific immune responses,
Th1 cells direct cell-mediated immunity and promote class
switching to IgG2a. Th2 cells direct humoral immunity and
promote class switching to IgG1 and IgA (39, 51). To date, the
mechanism determining Th1- or Th2-type immunity to a given
antigen is not well understood. Th2-type immune responses
are rare in the immune response elicited by attenuated Salmo-
nella vaccines (11, 41). While Th1-type dominant responses
were observed for the LPS and SOMPs in this study, mixed
Th1- and Th2-type immune responses were observed for
rPspA (Fig. 8). After 10 weeks postimmunization, the Th2-type
response became dominant. The mechanisms stimulating these
types of immune responses by the Salmonella-rPspA vaccine
remain unknown. It has been reported that oral immunization
of purified PspA with the mucosal adjuvant cholera toxin in
mice elicited Th2-type immune responses (57). In the devel-
opment of pneumococcal vaccines, the anti-rPspA IgG isotype
switching to a mixed or IgG1-dominant type along with a
mucosal IgA response, indicating induction of a strong Th2-
type humoral immune response, is preferred to prevent colo-
nization of S. pneumoniae in the respiratory tract (pneumonia)
or ear mucosa (otitis media) (33, 55). A sublethal challenge of
S. pneumoniae boosted the rPspA immune responses with
maintenance of the IgG1 isotype dominant response observed
before infection.
Mice orally vaccinated with Salmonella-rPspA vaccine were
significantly protected (60%) (P  0.05) against virulent S.
pneumoniae WU2 intraperitoneal challenge at 10 weeks
postimmunization. These results indicate that the Salmonella
8501 vaccine, which expresses the rPspA by an improved
antigen expression system, induces protective immunity against
pneumococcal infection, and they are consistent with the re-
sults demonstrating that the -helical portion of PspA repre-
sents a protective domain (7).
In conclusion, the results of this study demonstrate that a
recombinant attenuated Salmonella vaccine expressing rPspA
antigen elicited mixed Th1- and Th2-type immune responses to
rPspA and protected mice against pneumococcal challenge.
Recombinant attenuated Salmonella-rPspA vaccines may have
great potential for use for inducing effective protection against
pneumococci which establish infection via a mucosal surface.
However, there are some issues that need to be evaluated in
future studies. The factors causing augmented Th2-type im-
mune responses will be investigated. It remains to be examined
whether rPspA secretion could be associated with the forma-
tion of membrane vesicles. Further modifications of the rPspA
antigen expression construct may be required to enhance the
rPspA secretion and to induce antibodies which can opsonize
diverse pneumococcal strains with high avidity. Answers to
these questions will subsequently improve the recombinant
attenuated Salmonella-based pneumococcal vaccine.
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